Variability of Two Metabolomic Platforms in CKD | Zendy

Eugene P. Rhee | Zendy; Sushrut S. Waikar | Zendy; Casey M. Rebholz | Zendy; Zihe Zheng | Zendy; Régis Périchon | Zendy; Clary B. Clish | Zendy; Anne M. Evans | Zendy; Julián Ávila-Pacheco | Zendy; Michelle Denburg | Zendy; Amanda H. Anderson | Zendy; Ramachandran S. Vasan | Zendy; Harold I. Feldman | Zendy; Paul L. Kimmel | Zendy; Josef Coresh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Variability of Two Metabolomic Platforms in CKD

Author(s) -

Eugene P. Rhee,

Sushrut S. Waikar,

Casey M. Rebholz,

Zihe Zheng,

Régis Périchon,

Clary B. Clish,

Anne M. Evans,

Julián Ávila-Pacheco,

Michelle Denburg,

Amanda H. Anderson,

Ramachandran S. Vasan,

Harold I. Feldman,

Paul L. Kimmel,

Josef Coresh

Publication year - 2018

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.07070618

Subject(s) - metabolomics , medicine , analyte , metabolite , biomarker , computational biology , chromatography , chemistry , biology , biochemistry

Nontargeted metabolomics can measure thousands of low-molecular-weight biochemicals, but important gaps limit its utility for biomarker discovery in CKD. These include the need to characterize technical and intraperson analyte variation, to pool data across platforms, and to outline analyte relationships with eGFR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research